newsfilter
← Latest News
GlobeNewswire·

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Positive initial Phase 1 data for IMVT-1402 announced, bolstering best-in-class potentialInitial 600 mg multiple-ascending dose (MAD) cohort data for IMVT-1402 expected in November 2023Initial Phase 2 proof-of-concept